Basket | Login | Register

 
 
 
 

WP 5: Identification of biomarkers sensitive to disease progression (Clinical studies)

Work Packages

Pharmacog Logo

Main Objectives

  • To characterise the relationship between an integrated biomarker platform and cognitive performance to identify biomarker ‘handprint(s)’ (MATRIX) sensitive to disease progression from MCI to AD.
  • To test the prognostic value of the biomarker ‘handprint(s)’ (MATRIX) for stratification and/or enrichment of MCI patients for future clinical trials
  • To assess the value of functional decline (natural course of disease) detected by the biomarker ‘handprint’ (MATRIX) as primary clinical endpoints, as compared to standard cognitive assessments.
  • To define study design requirements for future evaluation of the therapeutic potential of disease modifying agents in the MCI population

WP Leads

Academic Lead: Pr Giovanni Frisoni (IRCCS-FBF, Italy)

Industry lead: Dr Olivier Blin (GSK)

WP Partners

Patient enrolling centres

Biotechs

Other

UnivMed, France

AlzProtect

AstraZeneca

University of Lille, France

Exonhit

GSK

University of Leipzig, Germany

ICDD

Novartis

University of Essen, Germany

Amonita Diagnostics

Roche

Aristotle University of Thessaloniki, Greece

Qualissima

MN institute, Italy

VU University, Amsterdam, The Netherlands

 

University of Foggia, Italy

IRCCS-FBF, Italy

   

IRCCS-SDN, Italy

   

University of Genoa, Italy

   

University of Perugia, Italy

   

UCSC, Italy

   

IDIBAPS, Spain

   

Patient enrolment update: June 2015

 

 
 

Last Updated: Friday 17 July 2015

 

 
  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations
 
 

Options